MINNEAPOLIS,
July 21, 2020 /PRNewswire/ -- Bio-Techne Corporation
(NASDAQ:TECH) today announced that Exosome Diagnostics, a
Bio-Techne brand, has completed validation testing for COVID-19
caused by the novel coronavirus (SARS-CoV-2) and now offers the
ExoCovid-19 test for detection of the virus in patient samples. The
ExoCovid-19 test will be performed in its CLIA-certified,
CAP-accredited laboratory.
Exosome Diagnostics, the world leader in developing exosomal
liquid biopsy-based diagnostic assays, has expanded its
high-complexity laboratory capabilities to perform qualitative
multiplexing nucleic acid analysis for the sensitive detection and
identification of SARS-CoV-2 virus in nasal, nasopharyngeal, and
bronchoalveolar lavage patient specimens.
Exosome Diagnostics has validated the CDC-approved assay which
has been granted Emergency Use Authorization (EUA) by the U.S. Food
and Drug Administration for detection of SARS-CoV-2. Unlike many of
the earlier tests currently available on the market, the
ExoCovid-19 collection kit offers a minimally invasive nasal swab
(anterior nares) which enables patients to comfortably self-collect
a specimen while maintaining physical distancing from a healthcare
provider.
"We continue to closely monitor the ongoing response to COVID-19
and are actively scaling our COVID-19 test offerings for multiple
specimen types to increase the availability of high-quality,
reliable, and easily-administered laboratory testing," said
Johan Skog, Chief Scientific Officer
at Exosome Diagnostics.
"Bio-Techne continues to leverage its deep scientific and
research expertise to help patients and healthcare providers fight
the COVID-19 crisis. This EUA assay is an important addition to our
growing portfolio products and services enabling solutions for this
evolving pandemic," said Chuck Kummeth, President and Chief
Executive Officer of Bio-Techne.
For more information on how to order tests, please
visit www.exosomedx.com/covid-19.
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Senior
Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-launch-of-exocovid-19-test-for-detection-of-sars-cov-2-in-patient-samples-301096642.html
SOURCE Bio-Techne Corporation